Centre De Cancerologue Du Grand Montpellier — Clinical Trial Site

68 Registered trials

31 Currently recruiting

Organisation

Centre De Cancerologue Du Grand Montpellier

Location

Montpellier, France

Identifier

ORG-100041704

Address

25 Rue De Clementville, 34070, France

Departments

03306
2302: Clinique Clementville
2309:Oncologie Médicale
2311 Oncology Medical
4410:Medical Oncology
Breast Oncology
Centre de Cancérologie
Centre de Cancérologie du Grand Montpellier
Clinical Research
Clinique privée
FRA005: NA
medical oncology
Medical Oncology Department
N/A
NA
Oncologie
Oncologie Médicale
Oncology
Oncology Department
Oncology-Radiotherapy
Oncology-Radiotherapy Unit
Pneumology
Service d'Oncologie
Service d'oncologie medicale
Service De Radiotherapie

Clinical trials at this site (68)

Search interface

Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Bladder Cancer 5 2021-10-26
Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended

2023-506177-35-00 Ovarian, fallopian tube, or primary peritoneal carcinom 11 2021-10-23
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended

2023-510015-19-00 Patients with histologically or cytologically documente 5 2019-02-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Prostate Cancer 10 2019-01-04
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended

2024-510645-34-00 RAS and B-RAF wild-type metastatic colorectal cancer. R 4 2017-06-28
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom… Ended

2024-512848-30-00 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER 4 2024-11-12
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip… Ended

2022-500418-24-00 Locally Recurrent Inoperable or Metastatic Triple Negat 10 2020-01-17
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4